Compare Enveric Biosciences Inc (ENVB) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Manhattan Associates Inc — how do they compare? Enveric Biosciences Inc trades at $1.58 (market cap $6.20M), while Manhattan Associates Inc trades at $192.71 (market cap $11.38B). The key difference: Manhattan Associates Inc is far larger — about 1835.5× Enveric Biosciences Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | MANH | |
|---|---|---|
Market Cap | $6.20M | $11.38B |
Sector | Health | Technology |
52-Week High | $17.40 | $220.19 |
52-Week Low | $1.27 | $120.88 |
Enterprise Value | $1.30M | $11.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
MANH trades at $189.98, down 2.92% on the day, but maintains a bullish technical outlook with strong moving average signals and a golden cross formation. The company reported Q2 2026 EPS of $1.39, beating estimates, with cloud revenue growth driving performance. However, high valuation ratios like a P/E of 55.93 and P/B of 72.26 suggest premium pricing. Recent news highlights an ongoing legal investigation into fiduciary duties by Rosen Law Firm, adding a layer of scrutiny.
The stock's upside is supported by analyst consensus with a $210.33 price target and 80% buy ratings, but risks include elevated valuations, potential legal overhangs, and projected net cash flow turning negative in 2026. Investors should weigh robust profitability metrics against these headwinds for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
